Cambrex Stock Price, Forecast & Analysis (NYSE:CBM)

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Cambrex Co. (NYSE:CBM) issued its earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to analysts' expectations of $132.78 million. Cambrex had a net margin of 5.96% and a return on equity of 5.38%. The firm's quarterly revenue was up 13.0% compared to the same quarter last year. During the same period last year, the company posted $0.76 earnings per share. View Cambrex's Earnings History.

Cambrex is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Cambrex.

5 brokerages have issued 12-month target prices for Cambrex's shares. Their forecasts range from $43.00 to $60.00. On average, they anticipate Cambrex's stock price to reach $52.40 in the next year. This suggests that the stock has a possible downside of 12.6%. View Analyst Price Targets for Cambrex.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cambrex.

Media headlines about CBM stock have trended positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cambrex earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Cambrex.

Cambrex saw a drop in short interest in October. As of October 31st, there was short interest totalling 1,110,000 shares, a drop of 5.1% from the September 30th total of 1,170,000 shares. Based on an average trading volume of 542,800 shares, the short-interest ratio is presently 2.0 days. Approximately 3.3% of the company's stock are sold short. View Cambrex's Current Options Chain.

Some companies that are related to Cambrex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), NVIDIA (NVDA), Intel (INTC), Juno Therapeutics (JUNO), Under Armour (UAA) and Broadcom (AVGO).

Cambrex's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include GW&K Investment Management LLC (1.35%), Gabelli Funds LLC (0.72%), GABELLI & Co INVESTMENT ADVISERS INC. (0.46%), Rhumbline Advisers (0.32%), New York State Teachers Retirement System (0.27%) and Summit Creek Advisors LLC (0.26%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

CBM stock was sold by a variety of institutional investors in the last quarter, including Public Employees Retirement Association of Colorado, Summit Creek Advisors LLC, Trillium Asset Management LLC, Confluence Investment Management LLC, Envestnet Asset Management Inc., First Trust Advisors LP, Tocqueville Asset Management L.P. and IMA Wealth Inc.. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen and Shawn Cavanagh. View Insider Buying and Selling for Cambrex.

CBM stock was acquired by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, GABELLI & Co INVESTMENT ADVISERS INC., Exane Asset Management, Dupont Capital Management Corp, Harvest Management LLC, GW&K Investment Management LLC, Tokio Marine Asset Management Co. Ltd. and Russell Investments Group Ltd.. View Insider Buying and Selling for Cambrex.

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBM stock can currently be purchased for approximately $59.92.

Cambrex has a market capitalization of $2.02 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.View Additional Information About Cambrex.

The official website for Cambrex is http://www.cambrex.com/.

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]